<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01651182</url>
  </required_header>
  <id_info>
    <org_study_id>TXA Liver - PK</org_study_id>
    <nct_id>NCT01651182</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid Versus Placebo for Blood to Reduce Perioperative Bleeding Post-liver Resection</brief_title>
  <official_title>Open Label, Non-Randomized, Study to Evaluate the Pharmacokinetics of Tranexamic Acid in Patients Undergoing Major Liver Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tranexamic acid (TXA) is an antifibrinolytic agent that has been shown to reduce blood loss
      and blood transfusion requirements in the following patient populations: multisystem trauma,
      liver transplantation, cardiac surgery and spine surgery. Patients undergoing major liver
      resection are at risk of severe perioperative blood loss and may also benefit from
      perioperative TXA administration.

      This open label, non-randomized study to evaluate the pharmacokinetic and pharmacodynamic
      properties of two well studied dosing regimens of TXA will provide guidance in determining
      the optimal TXA dosing regimen for patients undergoing major liver resection. Compelling
      evidence of the effectiveness of TXA comes from the large multicentred, multi-national
      CRASH-2 trial where TXA was administered as a 1 g bolus + 1 g infusion over 8 hours. In liver
      transplant surgery, the following dose regimen has been shown to have great effect:10 mg/kg/h
      from the start of surgery until 2 hours after reperfusion of the liver transplant.

      Although TXA is not currently approved for use in patients undergoing major liver resection,
      Health Canada has allowed the use of tranexamic acid for use in this research study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Receipt of blood transfusion(s)</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fibrinolytic Markers</measure>
    <time_frame>Baseline - Postoperative Day 0-7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Study</measure>
    <time_frame>Baseline - Postoperative Day 0-7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative incidence of symptomatic venous thromboembolic event</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other post-operative complications</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Cancer</condition>
  <condition>Tumour</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No tranexamic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 g bolus + 1 g infusion from induction over 8 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 g bolus + 10 mg/kg/hr from induction until end of surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No tranexamic acid</intervention_name>
    <description>Control</description>
    <arm_group_label>Standard Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_label>Dose 2</arm_group_label>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patient undergoing anticipated open or laparoscopic major liver resection (&gt; 2 hepatic
             segments), as assessed by the operating surgeon

          -  Age â‰¥ 18 years.

        Exclusion Criteria

          -  Previously enrolled in this study

          -  Platelet count less than 100,000/mm3

          -  Severe anemia (hemoglobin levels less than 90 g/l)

          -  Documented arterial or venous thrombosis at screening or in past three months

          -  Anticoagulants (other than LMWH or heparin in prophylactic doses to prevent deep vein
             thrombosis), direct thrombin inhibitors or thrombolytic therapy administered or
             completed within last week

          -  Hepatectomy associated with planned vascular or biliary reconstruction

          -  Known disseminated intravascular coagulation

          -  Severe renal insufficiency (CrCl&lt;30)

          -  History of seizure disorder

          -  Pregnant or lactating

          -  Hypersensitivity to tranexamic acid or any of the ingredients

          -  Unable to receive blood products (i.e. difficulty with cross matching, refuses blood
             transfusion, or a past history of unexplained severe transfusion reaction)

          -  Receipt of chemotherapy within 4 weeks of scheduled operation

          -  Patients undergoing resection for living donor liver transplant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Karanicolas, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2012</study_first_submitted>
  <study_first_submitted_qc>July 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2012</study_first_posted>
  <last_update_submitted>September 17, 2015</last_update_submitted>
  <last_update_submitted_qc>September 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood transfusion</keyword>
  <keyword>Blood loss</keyword>
  <keyword>Postoperative complications</keyword>
  <keyword>Outcome</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

